This process, which has been patented, is quite simple to set-up and robust in terms of reproducibility.
It allows the production of homogenous ADCs with a DAR control of 2:1 or 4:1 antibody/toxin ratios, in minimum synthesis steps.
Furthermore, in vitro studies aiming to compare ADCs activities from either commercial ADC models (Ex T-DM1, anti-HER-2) and the corresponding ones synthetized by our own process, revealed that our technology is up to guarantee an increased cytotoxic activity, on a more specific/targeted manner.
Internalization studies by ICMS & Flux imaging confirmed those points. Animal studies are on-going.
THE TECHNOLOGY IS AVAILABLE FOR LICENCE OR OTHER FORMS OF COLLABORATIONS TO
ANYONE INTERESTED TO DEVELOP THEIR OWN ADC(S).